Core Insights - Catalyst Pharmaceuticals (CPRX) reported adjusted earnings of 68 cents per share for Q1 2025, exceeding the Zacks Consensus Estimate of 53 cents and up from 38 cents in the same quarter last year [1] - Total revenues reached $141.4 million, reflecting a 44% year-over-year growth and surpassing the Zacks Consensus Estimate of $130 million [1] Revenue Breakdown - The primary revenue sources included Firdapse, Fycompa, and Agamree, with Firdapse generating $83.7 million in sales, a 25% increase year-over-year, exceeding estimates [2] - Fycompa, acquired in 2023, contributed $35.6 million in net product revenues, marking a 17% year-over-year growth and surpassing estimates [3] - Agamree generated $22 million in revenues, significantly up year-over-year, also beating estimates [7] Financial Position - As of March 31, 2025, Catalyst Pharmaceuticals had cash, cash equivalents, and investments totaling $580.7 million, an increase from $517.6 million at the end of 2024 [8] 2025 Financial Guidance - The company expects total revenues between $545 million and $565 million for 2025, driven by continued growth in product revenues from Firdapse and Agamree [9] - Firdapse revenues are projected between $355 million and $360 million, while Agamree revenues are anticipated to be between $100 million and $110 million [9] - Fycompa revenues are expected to be between $90 million and $95 million, reflecting anticipated market exclusivity loss [10] Research and Development - R&D expenses are projected to be between $15 million and $20 million in 2025, influenced by investments in the SUMMIT study for Agamree [11] - SG&A expenses are expected to rise "modestly" in 2025 [11]